Teplizumab can be used, within its marketing authorisation, as an option for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes. Teplizumab is only recommended if the company provides it according to the commercial arrangement.
Teplizumab must be funded in the NHS in England for the condition and population in the recommendations, if it is considered the most suitable treatment option. Teplizumab must be funded in England within 90 days of final publication of this guidance.
There is enough evidence to show that teplizumab provides benefits and value for money, so it can be used routinely across the NHS in this population.
NICE has produced tools and resources to support the implementation of this guidance.
There is no treatment available for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes.
For most people, type 1 diabetes is diagnosed at stage 3. But it may be diagnosed at stage 2. Usual treatment for stage 2 type 1 diabetes includes blood glucose monitoring, education and psychosocial support.
Clinical trial evidence shows that, compared with placebo, teplizumab delays progression to stage 3 type 1 diabetes.
There are some uncertainties in the economic model. But the most likely cost-effectiveness estimates for teplizumab are within the range NICE considers an acceptable use of NHS resources. So, teplizumab can be used.